Cargando…

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease

Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p-tau181, p-tau217 and p-tau231 measured using 10 assays to detect abnormal brain amyloid-β (Aβ) status and predict future progres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Janelidze, Shorena, Bali, Divya, Ashton, Nicholas J, Barthélemy, Nicolas R, Vanbrabant, Jeroen, Stoops, Erik, Vanmechelen, Eugeen, He, Yingxin, Dolado, Anna Orduña, Triana-Baltzer, Gallen, Pontecorvo, Michael J, Zetterberg, Henrik, Kolb, Hartmuth, Vandijck, Manu, Blennow, Kaj, Bateman, Randall J, Hansson, Oskar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115176/ https://www.ncbi.nlm.nih.gov/pubmed/36087307 http://dx.doi.org/10.1093/brain/awac333

Ejemplares similares

Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217
por: Groot, Colin, et al.
Publicado: (2022)

Correction: Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217
por: Groot, Colin, et al.
Publicado: (2022)

Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
por: De Meyer, Steffi, et al.
Publicado: (2022)

Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients
por: Pichet Binette, Alexa, et al.
Publicado: (2022)

Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
por: Kac, Przemysław R., et al.
Publicado: (2022)

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2021)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

Potential sources of interference on Abeta immunoassays in biological samples
por: Vanderstichele, Hugo, et al.
Publicado: (2012)

A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
por: Brum, Wagner S., et al.
Publicado: (2023)

Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios
por: Janelidze, Shorena, et al.
Publicado: (2023)

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
por: Bayoumy, Sherif, et al.
Publicado: (2021)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays
por: Leuzy, Antoine, et al.
Publicado: (2021)

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease
por: Hall, Sara, et al.
Publicado: (2020)

Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
por: Triana‐Baltzer, Gallen, et al.
Publicado: (2021)

Pathological Laughter Prodromal to a Stroke of the Head of the Left Caudate Nucleus
por: Beth Urhoy, Matthew, et al.
Publicado: (2022)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
por: Lantero-Rodriguez, Juan, et al.
Publicado: (2023)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
por: Cicognola, Claudia, et al.
Publicado: (2021)

Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid
por: Triana-Baltzer, Gallen, et al.
Publicado: (2020)

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2018)

Prodromal frontotemporal dementia: clinical features and predictors of progression
por: Benussi, Alberto, et al.
Publicado: (2021)

REM Sleep Behavior Disorder and Prodromal Neurodegeneration – Where Are We Headed?
por: Postuma, Ronald B., et al.
Publicado: (2013)

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease
por: Andersson, Emelie, et al.
Publicado: (2020)

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Bioinformatics tools and data resources for assay development of fluid protein biomarkers
por: Waury, Katharina, et al.
Publicado: (2022)

Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease
por: Doppler, Kathrin, et al.
Publicado: (2017)

Profiling classical neuropsychiatric biomarkers across biological fluids and following continuous lumbar puncture: A guide to sample type and time
por: Triana-Baltzer, Gallen, et al.
Publicado: (2022)

β-Secretase1 biological markers for Alzheimer’s disease: state-of-art of validation and qualification
por: Hampel, Harald, et al.
Publicado: (2020)

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Revealing the combined roles of Aβ and tau in Alzheimer’s disease via a pathophysiological activity decoder
por: Sanchez-Rodriguez, Lazaro M., et al.
Publicado: (2023)

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
por: Duits, Flora H., et al.
Publicado: (2018)

Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype
por: Janelidze, Shorena, et al.
Publicado: (2017)

Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
por: Gonzalez-Ortiz, Fernando, et al.
Publicado: (2023)

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
por: Groot, Colin, et al.
Publicado: (2022)

CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease
por: Mouton-Liger, François, et al.
Publicado: (2020)

Plasma p‐tau181/Aβ(1‐42) ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ(1‐42) and future cognitive decline
por: Fowler, Christopher J., et al.
Publicado: (2022)

Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders
por: Hall, Sara, et al.
Publicado: (2018)

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)
por: Vanderstichele, Hugo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fej6mot7n96rpp9v32ouklvlkh